Company Profile
Cellectar Biosciences Stock Price, News & Analysis
- Ticker:
- CLRB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.52 USD (0.00%)
Close
Last updated: August 6, 2026
21.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CLRB was little changed and closed at $2.52. No new same-company headline was identified in the current news window.
Company overview
Phospholipid Drug Conjugate Platform
Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.
Iopofosine I 131
Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical evidence in relapsed or refractory Waldenström macroglobulinemia. It has also been studied in multiple myeloma and central nervous system lymphoma.
CLR 125 Solid-Tumor Program
CLR 125 carries the Auger-emitting isotope iodine-125 and is being evaluated initially in triple-negative breast cancer, with potential application in lung and colorectal cancers.
Regulatory Strategy
Cellectar plans a confirmatory study of iopofosine in Waldenström macroglobulinemia to support a potential FDA filing under the Accelerated Approval pathway.
Future catalysts
Early dosimetry, safety, and efficacy data from the Phase 1b CLR 125 study in triple-negative breast cancer are expected around mid-2026, with additional updates during the year.
Initiation of the confirmatory iopofosine I 131 study in Waldenström macroglobulinemia is intended to support a subsequent Accelerated Approval filing.
Recent news
- 01
- 02
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Source: Cellectar Biosciences
- 03
- 04
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Source: Cellectar Biosciences
- 05
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Source: Cellectar Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cellectar Biosciences (CLRB)?
Cellectar Biosciences (CLRB) most recently closed at 2.52 USD, a 0.00% move versus the previous session.
What is the market cap of Cellectar Biosciences (CLRB)?
Cellectar Biosciences currently has a market capitalization of 21.9M USD on BioPharmSignal.
What does Cellectar Biosciences do?
Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure. Iopofosine I 131 Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical evidence in...
On which exchange is CLRB stock listed?
Cellectar Biosciences (CLRB) is associated with NASDAQ, United States, Biopharma.
What is Phospholipid?
Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.
Which conditions is Cellectar Biosciences targeting with Phospholipid?
Cellectar Biosciences is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Cellectar Biosciences describe recent progress with Phospholipid?
Early dosimetry, safety, and efficacy data from the Phase 1b CLR 125 study in triple-negative breast cancer are expected around mid-2026, with additional updates during the year. Initiation of the confirmatory iopofosine I 131 study in Waldenström macroglobulinemia is intended to support a subsequent Accelerated Approval filing.
What is Drug?
Phospholipid Drug Conjugate Platform Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.